Business
Mymetics to Advance Preclinical Studies for Virosome-based COVID-19 Vaccine through Innosuisse Grant
Mymetics to Advance Preclinical Studies for Virosome-based COVID-19 Vaccine through Innosuisse Grant.
About this update from Mymetics Corp.
[{"type":"text","content":"Mymetics continues to progress its Covid-19 vaccine development plan based on its virosome-vaccine platform.Mymetics, through its collaborator, the Department of Pneumology at the Inselspital, Bern University Hospital, in Switzerland, have received a grant from the Swiss Innovation Agency (Innosuisse) to investigate Mymetics' intranasal Covid-19 vaccine candidates in preclinical studies. This new study will complement Mymetics' other preclinical Covid-19 studies that are ongoing at Baylor College of Medicine in Texas USA and the Helmholtz Center of Infection Research in Germany.EPALINGES, SWITZERLAND / ACCESSWIRE / November 18, 2020 / Mymetics SA, a subsidiary of Mymetics Corporation (OTCQB:MYMX), a pioneer and leader in the research and development of virosome-based vaccines against life threatening and life disabling diseases, and Insel Gruppe AG, of which the Inselspital, Bern University Hospital, are part of, today announced that they have been awarded a grant from the Swiss Innovation Agency (Innosuisse). The grant will allow Mymetics in collaboration with the Department of Pneumology at the Inselspital, Bern University Hospital and the Department of Biomedical Research DBMR of Bern University to start a preclinical study which will investigate Mymetics' virosome-based Covid-19 nasal vaccine candidate for safety and tolerance, and its capacity to elicit protective respiratory immunity to block nasal infection and virus spreading to the lungs and brain.Since April 2020, Mymetics' goal is to develop a safe and highly effective virosome-based Covid-19 vaccine that can be easily administered to all age groups, particularly to immune compromised and elderly populations. The Company is thereby partnering with leading academic institutions to explore and select the best SARS-CoV antigens incorporated into virosome particles, while optimizing the route of administration and thermostability of the vaccine, before moving into human clinical trials.With the nasal vaccine, Mymetics aims to elicit not only a systemic, but also a protective respiratory immunity with a local memory mucosal immunity, which is often poorly induced by standard intramuscular vaccination.Prof. Thomas Geiser, the academic research leader of the project and Chairman and Chief Physician of Department of Pneumology at Inselspital, University Hospit...